Recent Posts
- EXINI executes agreement with INmune Bio for Phase I/II trial
- New version released of PYLARIFY AI® (aPROMISE)
- Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI® at the 2023 EuropeanAssociation of Nuclear Medicine (EANM) Annual Meeting
- EXINI Diagnostics AB, a Lantheus company (EXINI), announced today a ‘License and Development’ agreement with Curium, a world leader in nuclear medicine , to customize EXINI’s artificial intelligence (AI) platform for use in Europe.
- Lantheus Announces Presentations Featuring PYLARIFY AI® at the 2023 Society for NuclearMedicine and Molecular Imaging (SNMMI) Annual Meeting
Recent Comments
No comments to show.